Recruiting
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors - CA238-0001
Opdateret: 29 april, 2025 | ClinicalTrials.gov
Fase
Køn
Aldersinterval
Beliggenhed(er)
Recruiting
Inclusion Criteria: - Documented histologically or cytologically confirmed, advanced, unresectable/metastatic solid tumor measurable by RECIST v1.1. - CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B:. i) Locally advanced/metastatic, recurrent, or unresectable CRC with adenocarcinoma histology and whose disease has progressed after systemic cancer therapy in the metastatic or adjuvant setting including 5-FU, irinotecan, and/or oxaliplatin (if available and not contraindicated). - NSCLC: Part 2A-NSCLC/GC, 3L+ NSCLC:. i) Histologically confirmed NSCLC meeting stage criteria for Stage IIIB, Stage IV, or recurrent disease. ii) Progressed on at least 2 prior lines of therapy, iii) Participants must have received and progressed on or after anti-PD-(L)1 therapy, if available. - GC: Part 2A-NSCLC/GC, 2L+ GC:. i) Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting (or have progressed within 6 months of adjuvant therapy). ii) ECOG performance status of 0 or 1. Exclusion Criteria: - History of anaphylactic reactions to irinotecan and/or bevacizumab. - Previously received therapy targeting CEACAM5. - Grade ≥ 3 ILD/pneumonitis. - Other protocol-defined Inclusion/Exclusion criteria apply.
Hvis du vil rapportere en bivirkning, kan du indberette direkte til Lægemiddelstyrelsen via hjemmesiden www.meldenbivirkning.dk
Vi anbefaler at du også kontakter BMS for at rapportere bivirkninger.
Bivirkninger og andre rapporterbare begivenheder er defineret her
Rapporter bivirkninger eller klager over produktkvalitet: Medicinsk information
466-DK-2200001
